Vaxart's COVID-19 Data Delay and Norovirus Pause: A Mixed Blessing for a Cash-Constrained Biotech
Positive sentinel safety and expanded BARDA funding contrast with a slippage in the main cohort readout and a stalled norovirus partnership.
VXRT · Earnings Call · 2026-08-07
A Milestone Delivered, a Timeline Slipped
Vaxart's second-quarter fireside chat was defined by both achievement and delay. The company reported encouraging 12-month safety data from the 400-participant sentinel cohort of its Phase IIb COVID-19 trial, with “0 vaccine-related serious health complications and 0 severe or long-lasting adverse events in either group” — James Cummings, Chief Medical Officer · 2026-08-07 — a strong validation for the pill vaccine platform. Yet the much-anticipated efficacy readout from the ~5,000-person main cohort has slipped from prior guidance of Q4 2026 to “the first half of 2027” — James Cummings, Chief Medical Officer · 2026-08-07. This is a meaningful shift: in November, management had projected top-line data for Q4 2026 (component 2693558128316673068), and as recently as March 2026 they reiterated that guidance (component 6852913273626795195). The delay, attributed to BARDA protocols and contract modifications, raises questions about the pace of execution, even as the additional $29M in BARDA funding for deeper analyses signals continued government confidence.
BARDA's Double-Edged Sword
The June contract modification with BARDA releases funding for expanded exploratory analyses — including sentinel cohort subvariant sequencing and mucosal biomarker profiling. CFO Jeroen Grasman noted the new resources in context of the company's cash runway, which stands at $64M into Q2 2027. This is a positive, but it comes with strings: BARDA retains final authority over all readouts, as James Cummings reiterated:
our contract with BARDA provides the agency with the authority over the time and the content of all the readouts that we release.
The company's reliance on BARDA is a recurring theme — but the increased funding narrows the near-term dilution risk, as the company also retains a $25M Lincoln Park Capital facility.
Norovirus: Waiting on a Partner and on Moderna
A notable shift is the removal of the norovirus timeline from the corporate deck. Management cited that the program's Phase II start is contingent on funding, and they are aggressively pursuing partnerships and dilutive funding alternatives. The external landscape shifted as Moderna announced its own norovirus trial needs another season; CEO Steve Lo called it “a mixed blessing” — Steven Lo, Chief Executive Officer · 2026-08-07 — competitive advantage but also a new data point that potential partners weigh. This appears to be a strategic pause rather than a pivot, but the lack of a committed timeline weakens the near-term pipeline narrative.
Financials: Revenue Surge but Persistent Losses
Quarterly revenue was $27.2M, down from $39.7M a year ago, but that comparison reflects the lumpy nature of BARDA contract milestones. The fundamentals show a more volatile picture: Total Revenue spiked to $104M in Q4 2025 before falling back, and R&D spending has been cut sharply — down to $29M in the latest quarter from a recent peak of $76M. The company remains unprofitable, with net income of $5M in Q1 2026 driven by a one-time gain, but the underlying operating loss persists. The balance sheet is stretched; Effective net cash was -$6M at the last filing, though this excludes the BARDA receivables and the Lincoln Park facility. The price action reflects the uncertainty: the stock has fallen 18% over the past 90 days, with the long-term chart showing a 99.8% drawdown from its 2010 peak.
What Really Changed?
Three things stand out as genuinely new: (1) the sentinel safety dataset is out — a key derisking event; (2) the main cohort readout has been pushed back to 2027, a clear regression in timing; (3) the norovirus program has been officially deprioritized pending funding, a reversal from prior quarters where it was a headline asset. The governance changes, including the addition of Dr. Jim Breitmeyer and the formation of a Clinical and Regulatory Affairs Committee, are incremental but may signal a more shareholder-aligned strategy. The company's pivot to emphasizing the long COVID therapeutic potential of its oral vaccine is intriguing but exploratory.
Overall, this is a story of a high-risk biotech that has delivered one positive dataset but pushed the next big catalyst further out, while wrestling with a stalled partnership and a shrinking cash buffer. The market's muted reaction is telling; the company will need to execute with precision in the coming year to prove the platform's value.